Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The document serves as a notification of transactions involving directors and connected persons rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to disclosure of share transactions and contains no financial performance data.
Material Changes
No material changes to financial performance or business operations are reported in this filing. The document details specific changes in shareholdings for Sir Andrew Witty, a Director:
- Disposal of 50 Ordinary shares by gift on February 7, 2014.
- Transfer of 500 Ordinary shares by gift to a child on February 7, 2014.
- Transfer of 1,250 Ordinary shares by gift to another child on February 10, 2014.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risk factors, or discussion of contingencies. It strictly addresses compliance with Disclosure and Transparency Rules regarding director share transactions.
Investor Verification Points
- Confirm the total number of shares held by Sir Andrew Witty following these specific gift transactions.
- Verify if these transactions were part of a broader pre-arranged trading plan or routine estate planning.
- Note that this filing does not contain financial results; investors should refer to the company's Form 20-F or interim reports for financial data.